David A. Mankoff mostly deals with Breast cancer, Nuclear medicine, Positron emission tomography, Internal medicine and Radiology. David A. Mankoff interconnects Locally advanced, Chemotherapy and Pathology in the investigation of issues within Breast cancer. His study on Standardized uptake value and Fluorodeoxyglucose is often connected to Kinetic analysis and Thymidine kinase 1 as part of broader study in Nuclear medicine.
The study incorporates disciplines such as Cancer, Mediastinum, Lymph node, Bone scintigraphy and Primary tumor in addition to Positron emission tomography. The Internal medicine study combines topics in areas such as Surgery, Oncology and Systems biology. His Radiology study integrates concerns from other disciplines, such as Appropriate Use Criteria, Retrospective cohort study, Breast carcinoma, Breast cancer screening and Breast ultrasound.
His scientific interests lie mostly in Breast cancer, Internal medicine, Nuclear medicine, Positron emission tomography and Oncology. His Breast cancer study incorporates themes from Radiology, Chemotherapy and Pathology. The concepts of his Nuclear medicine study are interwoven with issues in Locally advanced, Prospective cohort study and Progression-free survival.
His Positron emission tomography research focuses on Molecular imaging and how it connects with Medical physics and Cancer therapy. His research integrates issues of Biomarker, Primary tumor and Disease in his study of Oncology. His Cancer research integrates issues from Cancer research and Clinical trial.
David A. Mankoff focuses on Internal medicine, Oncology, Cancer, Breast cancer and Positron emission tomography. His Oncology study also includes fields such as
His study in Breast cancer is interdisciplinary in nature, drawing from both Fluorodeoxyglucose, Radiology, Nuclear medicine and Disease. David A. Mankoff usually deals with Nuclear medicine and limits it to topics linked to Progression-free survival and Progressive disease. The study incorporates disciplines such as Molecular imaging, Magnetic resonance imaging, Prostate cancer and Iterative reconstruction in addition to Positron emission tomography.
David A. Mankoff mainly focuses on Cancer, Internal medicine, Oncology, Breast cancer and Positron emission tomography. His studies in Cancer integrate themes in fields like Ex vivo, Cancer research, Antibiotics, Biodistribution and MEDLINE. His study in the field of Ischemia, Myocardial infarction, Stroke and Blood flow also crosses realms of Fractional flow reserve.
His Oncology research includes themes of Magnetic resonance imaging, Clinical trial and Ovarian cancer. His biological study spans a wide range of topics, including Clinical endpoint, Radiology and Nuclear medicine. His Positron emission tomography research is multidisciplinary, incorporating perspectives in Molecular imaging, Computational physics and Estimation theory.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials
Lalitha K. Shankar;John M. Hoffman;Steve Bacharach;Michael M. Graham.
The Journal of Nuclear Medicine (2006)
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Gary J. Kelloff;John M. Hoffman;Bruce Johnson;Howard I. Scher.
Clinical Cancer Research (2005)
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Laurie L. Carr;David A. Mankoff;Bernardo H. Goulart;Keith D. Eaton.
Clinical Cancer Research (2010)
Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer
Hannah M. Linden;Svetlana A. Stekhova;Jeanne M. Link;Julie R. Gralow.
Journal of Clinical Oncology (2006)
Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.
Joseph G. Rajendran;David A. Mankoff;Finbarr O'Sullivan;Lanell M. Peterson.
Clinical Cancer Research (2004)
Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer
Hans-Anton Lehr;David A. Mankoff;David Corwin;Guiseppe Santeusanio.
Journal of Histochemistry and Cytochemistry (1997)
Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy
David A. Mankoff;Lisa K. Dunnwald;Julie R. Gralow;Georgiana K. Ellis.
The Journal of Nuclear Medicine (2002)
A definition of molecular imaging
David A Mankoff.
The Journal of Nuclear Medicine (2007)
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
Lucy Sasongko;Jeanne M. Link;Mark Muzi;David A. Mankoff.
Clinical Pharmacology & Therapeutics (2005)
Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol
Lanell M. Peterson;David A. Mankoff;Thomas Lawton;Kevin Yagle.
The Journal of Nuclear Medicine (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: